Longitudinal corneal endothelial cell loss after corrective surgery for late in-the-bag IOL dislocation: a randomized
Marius Dalby1, Olav Kristianslund, Atle Einar Østern
1From the Department of Ophthalmology (Dalby, Kristianslund, Østern, Drolsum), Oslo Centre for Biostatistics and Epidemiology (Falk), Oslo University Hospital, Institute of Clinical Medicine, University of Oslo (Dalby, Drolsum), Oslo, Norway.
Purpose:
To compare safety regarding longitudinal corneal endothelial cell loss (ECL) after IOL exchange vs IOL repositioning for late in-the-bag IOL dislocation.
Setting:
Oslo University Hospital, Norway.
Design:
Prospective, parallel group, randomized clinical trial.
Methods:
During a 3-year period, 104 patients were randomly assigned to groups receiving either IOL exchange with retropupillary fixation of an iris-claw IOL (n = 50) or IOL repositioning by scleral suturing (n = 54). All operations were performed by 1 surgeon with an anterior approach. Endothelial cell density (ECD) and central corneal thickness were measured preoperatively and at 6 months, 1 year, and 2 years postoperatively. A linear mixed model was applied for the longitudinal analysis, where patients with at least 1 ECD measurement were included (n = 44 exchange; n = 50 repositioning). The main outcome measure was 2-year longitudinal ECL in IOL exchange compared with IOL repositioning.
Results:
The longitudinal ECL was similar between the IOL exchange (n = 44) and IOL repositioning (n = 50) groups during the 2 years of follow-up (17.5% vs 15.3%, P = .15). A subgroup analysis found no reason to advise against either method for patients with low preoperative ECD (<1500 cells/mm). The mean central corneal thickness was similar between the 2 groups and remained stable over 2 years of follow-up.
Conclusions:
This randomized clinical trial of late in-the-bag IOL dislocation surgery found that exchanging the IOL was as safe as repositioning in terms of 2-year longitudinal ECL.
Related Concept Videos
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...


